Intracranial response rate was in line with previous reports using BRAF and MEK inhibitors in patients with metastatic melanoma with BM.5 Despite the good response rates, the duration of the response was shorter than in patients without BM, 5.6 months versus 18.6 months reported in the COLUMBUS trial, this is also true for OS (15.9 months in our study versus 33.6 months respectively).8 These differences in PFS and OS were also present when comparing dabrafenib and trametinib in patients with5 and without6 brain metastases in pivotal clinical trials (COMBI-MB). Here, MAP2K7 is linked to metastatic melanoma.